FAQ on Scinai Immunotherapeutics' Loan Restructuring Agreement with EIB

What is the main topic of the announcement?

The announcement details Scinai Immunotherapeutics’ completion of a loan restructuring agreement with the European Investment Bank, involving the conversion of a significant portion of its debt into preferred shares.

Why is this agreement significant for Scinai Immunotherapeutics?

This agreement significantly reduces Scinai’s debt burden by converting approximately EUR 26.6 million into preferred shares, leaving only EUR 250,000 outstanding, which is not due until Dec. 31, 2031, and does not accrue interest.

How does the loan restructuring work?

The agreement converts EUR 26.6 million of debt into 1,000 preferred shares of the company, reducing the outstanding loan amount to EUR 250,000, which has a maturity date of Dec. 31, 2031, and does not accrue interest.

Who is involved in this agreement?

Scinai Immunotherapeutics and the European Investment Bank (EIB) are the parties involved in this loan restructuring agreement.

When does the remaining loan amount mature?

The remaining EUR 250,000 of the loan is due on Dec. 31, 2031, and cannot be prepaid before this date.

What are the implications of this agreement for Scinai?

This restructuring improves Scinai’s financial flexibility by reducing its immediate debt obligations and eliminating interest on the remaining loan amount, allowing the company to focus on its biopharmaceutical and CDMO services.

Where can I find more information about Scinai Immunotherapeutics?

More information about Scinai Immunotherapeutics can be found on their website at www.Scinai.com or in the company’s newsroom at https://ibn.fm/SCNI.

What should investors know about this agreement?

Investors should note that this agreement significantly reduces Scinai’s debt and interest obligations, potentially improving the company’s financial health and its ability to invest in its biopharmaceutical and CDMO services.